PARP inhibitors: the journey from research hypothesis to clinical approval

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancer presents a significant global health challenge, necessitating innovative therapeutic strategies.
• Tumors exhibit diverse molecular alterations across various hallmarks, including DNA damage response (DDR).
• Exploiting DDR defects offers a promising avenue for targeted cancer therapy.

Purpose of the Study:

• This review focuses on the therapeutic potential of targeting the DNA damage response (DDR) pathway in cancer.
• To explore how DDR defects can be leveraged for improved cancer treatment efficacy and reduced toxicity.

Main Methods:

• Review of current literature on DNA damage response (DDR) pathways in cancer.
• Analysis of therapeutic strategies targeting DDR, including chemotherapy, radiotherapy, and novel agents.
• Examination of synthetic lethality approaches, exemplified by Poly-(ADP-ribose) polymerase (PARP) inhibitors.

Main Results:

• Defects in DNA damage response (DDR) are implicated in cancer development and can be therapeutically exploited.
• Targeted DDR inhibition can enhance the efficacy of conventional therapies like chemotherapy and radiotherapy.
• Poly-(ADP-ribose) polymerase (PARP) inhibitors represent a successful clinical application of targeting DDR defects through synthetic lethality.

Conclusions:

• Targeting the DNA damage response (DDR) pathway offers a precise approach to cancer treatment.
• Exploiting synthetic lethality in tumors with specific DDR defects, such as with PARP inhibitors, improves treatment outcomes.
• Further development of DDR-targeting drugs promises increased efficacy and decreased toxicity in cancer therapy.